• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Patient attrition in Molecular Tumour Boards: a systematic review

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    35941175.pdf
    Size:
    906.1Kb
    Format:
    PDF
    Description:
    Identified with Open Access button
    Download
    Authors
    Frost, Hannah
    Graham, Donna
    Carter, Louise
    O'Regan, Paul
    Landers, Donal
    Freitas, Andre
    Affiliation
    Digital Experimental Cancer Medicine Team, Cancer Research UK Manchester Institute Cancer Biomarker Centre, Manchester, UK.
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Background: Molecular Tumour Boards (MTBs) were created with the purpose of supporting clinical decision-making within precision medicine. Though in use globally, reporting on these meetings often focuses on the small percentages of patients that receive treatment via this process and are less likely to report on, and assess, patients who do not receive treatment. Methods: A literature review was performed to understand patient attrition within MTBs and barriers to patients receiving treatment. A total of 51 papers were reviewed spanning a 6-year period from 11 different countries. Results: In total, 20% of patients received treatment through the MTB process. Of those that did not receive treatment, the main reasons were no mutations identified (27%), no actionable mutations (22%) and clinical deterioration (15%). However, data were often incomplete due to inconsistent reporting of MTBs with only 55% reporting on patients having no mutations, 55% reporting on the presence of actionable mutations with no treatment options and 59% reporting on clinical deterioration. Discussion: As patient attrition in MTBs is an issue which is very rarely alluded to in reporting, more transparent reporting is needed to understand barriers to treatment and integration of new technologies is required to process increasing omic and treatment data.
    Citation
    Frost H, Graham DM, Carter L, O'Regan P, Landers D, Freitas A. Patient attrition in Molecular Tumour Boards: a systematic review. British journal of cancer. 2022 Aug 8. PubMed PMID: 35941175. Epub 2022/08/09. eng.
    Journal
    British Journal of Cancer
    URI
    http://hdl.handle.net/10541/625556
    DOI
    10.1038/s41416-022-01922-3
    PubMed ID
    35941175
    Additional Links
    https://dx.doi.org/10.1038/s41416-022-01922-3
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1038/s41416-022-01922-3
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Genomic expertise in action: molecular tumour boards and decision-making in precision oncology.
    • Authors: Bourret P, Cambrosio A
    • Issue date: 2019 Nov
    • Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
    • Authors: Koopman B, Groen HJM, Ligtenberg MJL, Grünberg K, Monkhorst K, de Langen AJ, Boelens MC, Paats MS, von der Thüsen JH, Dinjens WNM, Solleveld N, van Wezel T, Gelderblom H, Hendriks LE, Speel EM, Theunissen TE, Kroeze LI, Mehra N, Piet B, van der Wekken AJ, Ter Elst A, Timens W, Willems SM, Meijers RWJ, de Leng WWJ, van Lindert ASR, Radonic T, Hashemi SMS, Heideman DAM, Schuuring E, van Kempen LC
    • Issue date: 2021 Aug
    • Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.
    • Authors: Ciliberto G, Canfora M, Terrenato I, Agnoletto C, Agustoni F, Amoroso L, Baldassarre G, Curigliano G, Delmonte A, De Luca A, Fiorentino M, Gregorc V, Ibrahim T, Lazzari C, Mastronuzzi A, Pronzato P, Santoro A, Scambia G, Tommasi S, Vingiani A, Giacomini P, De Maria R
    • Issue date: 2022 Oct 17
    • Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.
    • Authors: Willemsen AECAB, Krausz S, Ligtenberg MJL, Grünberg K, Groen HJM, Voest EE, Cuppen EPJG, van Laarhoven HWM, van Herpen CML
    • Issue date: 2019 Jul
    • Molecular screening programs in different countries: what we learned and perspectives.
    • Authors: Borcoman E, Le Tourneau C, Kamal M
    • Issue date: 2019 Sep
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.